Mesenchymal Stromal Cells for ARDS (COVID positive and COVID negative)

**Disease Area:** COVID-19  
**Investigator:** Michael Matthay  
**Institution:** University of California, San Francisco  
**CIRM Grant:** CLIN2COVID19-11823  
**Award Value:** $701,049  
**Trial Sponsor:** University of California, San Francisco  
**Trial Stage:** Phase 2  
**Trial Status:** Recruiting  
**Targeted Enrollment:** 120  
**ClinicalTrials.gov ID:** NCT03818854

**Details:**
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that occurs when fluid leaks into the lungs. As a result, breathing becomes difficult and oxygen cannot get into the body. ARDS is one of the most serious and lethal consequence of COVID-19.

This clinical trial will use Mesenchymal Stromal Cells (MSCs) for the treatment of ARDS, including both COVID-19 positive and COVID-19 negative patients, with the hopes of improving oxygenation.

**Design:**
Phase 2B trial

**Goal:**
Test safety and efficacy.

**Source URL:** https://www.cirm.ca.gov/clinical-trial/mesenchymal-stromal-cells-ards-covid-positive-and-covid-negative